Literature DB >> 20412290

Inflammation reduces HDL protection against primary cardiac risk.

James P Corsetti1, Ron T Gansevoort, Charles E Sparks, Robin P F Dullaart.   

Abstract

BACKGROUND: We recently reported high high-density lipoprotein (HDL) cholesterol as a predictor of recurrent risk in a subgroup of postinfarction patients defined by hypercholesterolemia and high C-reactive protein (CRP) levels. We investigated whether a similar high-risk subgroup might exist for incident cardiovascular disease.
MATERIAL AND METHODS: A graphical exploratory data analysis tool was used to identify high-risk subgroups in a male population-based cohort (n = 3405) from the prevention of renal and vascular end-stage disease study by generating 3-dimensional mappings of risk over the HDL-cholesterol/CRP domain with subsequent use of Kaplan-Meier analysis to verify high-risk. Within-subgroup risk was assessed using Cox proportional hazards regression and Kaplan-Meier analysis.
RESULTS: Mappings revealed two high-risk subgroups: a low HDL-cholesterol/high CRP subgroup and a high HDL-cholesterol/high CRP subgroup. The low HDL-cholesterol subgroup demonstrated a pattern of metabolic syndrome dyslipidemia contrasted with a predominantly unremarkable biomarker pattern for the high HDL-cholesterol subgroup. However, in the high HDL-cholesterol subgroup, CRP levels were higher than the low HDL-cholesterol subgroup; and within the high HDL-cholesterol subgroup, CRP predicted risk. Moreover, in the high HDL-cholesterol subgroup, risk was associated with lower triglyceride levels in conjunction with presumptively larger HDL particles.
CONCLUSIONS: High HDL-cholesterol and high CRP levels define a subgroup of men at high-risk for incident cardiovascular disease. High HDL cholesterol-associated risk likely relates to impaired HDL particle remodelling in the setting of inflammation. This approach may facilitate identification of additional inflammation-related mechanisms underlying high HDL cholesterol-associated risk; and potentially influence management of such patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412290     DOI: 10.1111/j.1365-2362.2010.02287.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  20 in total

1.  Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Authors:  James P Corsetti; Ron T Gansevoort; Stephan J L Bakker; Charles E Sparks; Priya Vart; Robin P F Dullaart
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

2.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

3.  Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels.

Authors:  James P Corsetti; Dan Ryan; David L Rainwater; Arthur J Moss; Wojciech Zareba; Charles E Sparks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-20       Impact factor: 8.311

4.  Statin treatment improves plasma lipid levels but not HDL subclass distribution in patients undergoing percutaneous coronary intervention.

Authors:  Li Tian; Yucheng Chen; Chuanwei Li; Zhi Zeng; Yanhua Xu; Shiyin Long; Mingde Fu
Journal:  Lipids       Date:  2012-12-29       Impact factor: 1.880

5.  A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality.

Authors:  Robert W McGarrah; Jacob P Kelly; Damian M Craig; Carol Haynes; Ryan C Jessee; Kim M Huffman; William E Kraus; Svati H Shah
Journal:  Clin Chem       Date:  2016-11-03       Impact factor: 8.327

Review 6.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

Review 7.  HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Nat Rev Cardiol       Date:  2011-02-08       Impact factor: 32.419

8.  Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study.

Authors:  David M Tehrani; Julius M Gardin; David Yanez; Calvin H Hirsch; Donald M Lloyd-Jones; Phyllis K Stein; Nathan D Wong
Journal:  Atherosclerosis       Date:  2013-09-05       Impact factor: 5.162

9.  High-density lipoprotein cholesterol and causes of death in chronic kidney disease.

Authors:  Sankar D Navaneethan; Jesse D Schold; Carl P Walther; Susana Arrigain; Stacey E Jolly; Salim S Virani; Wolfgang C Winkelmayer; Joseph V Nally
Journal:  J Clin Lipidol       Date:  2018-03-30       Impact factor: 4.766

10.  Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation.

Authors:  Nhat-Tu Le; James P Corsetti; Janet L Dehoff-Sparks; Charles E Sparks; Keigi Fujiwara; Jun-Ichi Abe
Journal:  Int J Inflam       Date:  2012-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.